Ona Therapeutics and Biocytogen Strike Deal to Progress Antibody-Drug Conjugates

Biocytogen Pharmaceuticals and Ona Therapeutics have collaborated to progress an antibody-drug conjugate therapy that targets neoplasms.  

Ona will have the opportunity to examine human antibodies generated using Biocytogen’s RenMice technology, targeting a specific neoplasm. 

Additionally, Ona has the choice to pursue the acquisition of a sole license to research, manufacture, and sell ADCs in regions that have been selected by the firms. 

Dr Yuelei Shen, Biocytogen’s head executive, commented, “As part of Project Integrum, Biocytogen has been discovering fully human antibodies against 200 TAA targets based on their internalisation activity.” 

Dr Valerie Vanhooren, the head chief of Ona Therapeutics, stated, “We believe the combination of Biocytogen’s rich antibody repertoire with Ona’s unique insight in advanced cancer biology will have great advantages in the discovering and developing of first-in-class molecules for unmet medical needs.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.